{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:34:34Z","timestamp":1790174074640,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T00:00:00Z","timestamp":1137542400000},"content-version":"vor","delay-in-days":231,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> We evaluated the association of anti\u2010cyclic citrullinated peptide (CCP) antibody titers with serological markers of disease activity. We also compared three different anti\u2010CCP antibody ELISAs with an anti\u2010citrullin ELISA and the IgM and the IgA rheumatoid factor (RF) in their performance of discriminating between rheumatoid arthritis (RA) and other rheumatic diseases. Sera from 333 consecutive patients of the Rheumaeinheit der Medizinischen Poliklinik Munchen, an outpatient clinic for rheumatic diseases, were collected and tested. Anti\u2010CCP antibodies were assayed with three different commercially available ELISAs. Antifilaggrin antibodies were tested with a commercially available ELISA using <jats:italic>in vitro<\/jats:italic> deiminated recombinant rat filaggrin. IgA\u2010RF was analyzed with an ELISA, whereas IgM\u2010RF was measured by latex\u2010enhanced turbidimetry. Rheumatoid arthritis (RA) was diagnosed in 87 patients according to the revised classification criteria of the American College of Rheumatology (ACR), probable RA was diagnosed in 23 patients in an early phase not (yet) fulfilling the ACR criteria, and 223 patients had other rheumatic diseases. Differences in sensitivity and specificity were calculated using McNemar's test. A measure of agreement (kappa statistic) was used to examine whether the tests tended to identify the same patients as positive or negative. Correlations between CCP titers and other tests were analyzed by Spearman nonparametric rank correlation. No significant differences in sensitivity and specificity were found between the tested CCP assays (80.0\u201080.9% and 97.3\u201098.1%, respectively). All three CCP tests were slightly but not significantly more sensitive and specific than the anti\u2010citrullin assay (77% and 92%, respectively), comparably sensitive but significantly more specific compared with the IgM\u2010RF (86% and 82%, respectively), and significantly more sensitive but comparably specific compared with the IgA\u2010RF (63% and 94.4%, respectively) in detecting the patients with RA. There was no significant correlation between anti\u2010CCP, anti\u2010citrullin, or IgM\u2010RF or IgA\u2010RF antibody titers and C\u2010reactive protein, erythrocyte sedimentation rate, or white blood cell count. A weak but significant linear correlation was found between anti\u2010CCP titers and IgM\u2010RF titers (<jats:italic>r<\/jats:italic>= 0.2, <jats:italic>P<\/jats:italic>= 0.03). We could not find a significant difference between the three tested anti\u2010CCP assays and the anti\u2010citrullin test in terms of sensitivity and specificity. Compared with the IgM\u2010RF, all the anti\u2010CCP assays were superior in specificity and comparable in sensitivity. Compared with the IgA\u2010RF, they were more sensitive and comparably specific in the discrimination of patients with RA from other rheumatic diseases. No correlation of any tested autoantibody titer with serological parameters of inflammation was found.<\/jats:p>","DOI":"10.1196\/annals.1313.031","type":"journal-article","created":{"date-parts":[[2005,7,12]],"date-time":"2005-07-12T19:14:25Z","timestamp":1121195665000},"page":"295-303","source":"Crossref","is-referenced-by-count":71,"title":["Association of Anti\u2010Cyclic Citrullinated Peptide Antibodies, Anti\u2010Citrullin Antibodies, and IgM and IgA Rheumatoid Factors with Serological Parameters of Disease Activity in Rheumatoid Arthritis"],"prefix":"10.1111","volume":"1050","author":[{"given":"ALEXANDER","family":"GREINER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HERBERT","family":"PLISCHKE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HERBERT","family":"KELLNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RUDOLF","family":"GRUBER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","article-title":"New drugs for rheumatoid arthritis","volume":"350","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200405000-00013"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780321204"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.7.620"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116713"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.7.809"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cccn.2004.07.016"},{"issue":"1","key":"e_1_2_6_10_2","first-page":"S17","article-title":"Anti\u2010CCP antibodies: the new rheumatoid factor in the serology of rheumatoid arthritis","volume":"3","author":"Venrooij W.J.","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/08916930410001708733"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019992"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2004.08.005"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1316"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016808"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740310004856"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10117"},{"key":"e_1_2_6_18_2","first-page":"689","article-title":"The prognostic value of the antiperinuclear factor, anti\u2010citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis","volume":"17","author":"Jaarsveld C.H.","year":"1999","journal-title":"Clin. Exp. Rheumatol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar93"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/47.6.1089"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740310003677"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.3.261"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.870"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019877"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11223"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg184"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.427"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.1.32"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02341.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg257"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1313.031","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1313.031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:12:17Z","timestamp":1695618737000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1313.031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1196\/annals.1313.031"],"URL":"https:\/\/doi.org\/10.1196\/annals.1313.031","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}